Prescient Therapeutics exceeds SPP target, delivers top-up placement to accommodate demand
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing...
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing...
CellPryme-A is the latest in a portfolio of platform cell technologies that can not only...
Prescient Therapeutics Ltd (ASX:PTX) has been invited to present two sessions at the upcoming CAR-TCR Summit...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
"We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward...
Prescient Therapeutics Ltd (ASX:PTX) managing director and CEO Steven Yatomi-Clarke speaks with Proactive’s Elisha Newell about...
Prescient Therapeutics Ltd (ASX:PTX) has entered into a five-year manufacturing services agreement with specialist cell therapy...
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion...
“The fact of the matter is there are people walking around now who shouldn’t be...
Prescient Therapeutics Ltd (ASX:PTX)’s PTX-100 for the treatment of peripheral T-cell lymphomas (PTCL) has been...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.